The Ledger

Every statement that passed quotation and attribution checks. Mix any filter with any other: certainty 1/5, debate potential 5/5, or both at once.

clear all ✕

why aren't all 7 resolved? a statement only gets an assessment when the public record can support or contradict it. opinions and what-ifs never can, and 0 checkable ones are still open, waiting for their date. predictions held up or didn't; assertions are supported or contradicted. on every card: ▮▮▮▮▮ certainty · ▮▮▮▮▮ debate potential. speakers are clickable

Assertion Partly supported
Dave Ricks: Medicare rules prohibit covering weight-loss drugs unless patients have diabetes
“If you're say on Medicare, currently the rule of the federal government is they won't pay. For these medications. You have to get diabetes before you can get the drug.”
Dave Ricks Oct 8, 2024 ▶ 28:23 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Partly supported
Eli Lilly retains only one-third of gross drug prices after PBM cuts
“Two thirds of actually our gross price goes to PBMs and insurance companies. So of the gross price that's often quoted, the net for us is about a third of that.”
Dave Ricks Oct 8, 2024 ▶ 45:06 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Partly supported
Dave Ricks: Half of public biotech companies trade at or below cash
“Half of biotech that's publicly traded is trading at or below cash.”
Dave Ricks Sep 29, 2025 ▶ 13:35 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Assertion Partly supported
Dave Ricks: About 50% of employer-sponsored health plans cover GLP-1 weight-loss drugs
“Right now about 50% of the employer-sponsored insurance plans cover it.”
Dave Ricks Oct 8, 2024 ▶ 30:49 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Partly supported
Dave Ricks: 10 to 11 million Americans currently take GLP-1 drugs
“We only have 10 or eleven million Americans on these drugs.”
Dave Ricks Oct 8, 2024 ▶ 39:28 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Partly supported
Ricks: Eli Lilly GLP-1 launched at 20% discount to Novo Nordisk
“We launched at a 20% discount to Nova's product, even though we have better efficacy data, and we've only cut the price since then.”
Dave Ricks Oct 8, 2024 ▶ 45:44 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Partly supported
Eli Lilly spends $14.2 billion on R&D, equal to 25% of sales
“We spent 25% of sales on R&D. This year that'll be 14.2 billion dollars.”
Dave Ricks Sep 29, 2025 ▶ 9:00 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 460 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.